The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting revised financial outlooks for the professional services and biotechnology sectors, analysts from Stifel and Morgan Stanley issued updated ratings for ADP and Gilead Sciences. Stifel raised its price target for ADP to $260 while maintaining a 'Hold' rating, whereas Morgan Stanley kept a 'Buy' rating on Gilead Sciences (GILD) but lowered its price target to $166. These adjustments reflect updated analyst perspectives on the companies' financial prospects and market valuations under current conditions.
These evaluations come as investors monitor the biotech sector's performance, where Gilead Sciences has shown continued growth in oncology drug sales, according to prior quarter earnings data. Compared to peers, ADP faces competitive pressure from firms like Paychex, which recently reported strong financial results, justifying Stifel's cautious 'Hold' stance despite the target increase. These moves are part of a broader wave of re-evaluating large-cap equities in the US market.
Regarding trading levels, ADP shares stood at $239.49 at close July 06, 2026, while GILD shares settled at $129.61 at close July 06, 2026. Traders should monitor upcoming US labor market data, as ADP is directly sensitive to employment trends, especially following the early July Non Farm Payrolls report which showed 57k jobs added, significantly missing the 110k forecast.